BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+17.56%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$6.54B
AUM Growth
+$6.54B
(+5.3%)
Cap. Flow
-$366M
Cap. Flow
% of AUM
-5.6%
Top 10 Holdings %
Top 10 Hldgs %
39.82%
Holding
179
New
25
Increased
33
Reduced
89
Closed
18
Top Buys
| 1 |
Immunocore
IMCR
|
$65.3M |
| 2 |
Biohaven
BHVN
|
$46M |
| 3 |
Moderna
MRNA
|
$41.1M |
| 4 |
GE HealthCare
GEHC
|
$40.4M |
| 5 |
Boston Scientific
BSX
|
$30.3M |
Top Sells
| 1 |
Vertex Pharmaceuticals
VRTX
|
$108M |
| 2 |
UnitedHealth
UNH
|
$63.2M |
| 3 |
Evolent Health
EVH
|
$42.9M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$34.5M |
| 5 |
IQVIA
IQV
|
$34M |
Sector Composition
| 1 | Healthcare | 99.06% |
| 2 | Industrials | 0.83% |
| 3 | Energy | 0.03% |
| 4 | Consumer Discretionary | 0.02% |
| 5 | Communication Services | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
UnitedHealth
UNH
$279B
| $72.7M | 1.11% |
138,152
-120,053
| -46% | -$63.2M |
|
27
Pacific Biosciences
PACB
$378M
| $71.8M | 1.1% |
7,317,128
+71,940
| +1% | +$706K |
|
28
Insmed
INSM
$30.3B
| $71M | 1.09% |
2,290,958
-871,777
| -28% | -$27M |
|
|
29
Immunocore
IMCR
$1.78B
| $66.7M | 1.02% |
976,054
+956,204
| +4,817% | +$65.3M |
|
30
Relay Therapeutics
RLAY
$709M
| $65.4M | 1% |
5,936,082
+1,051,082
| +22% | +$11.6M |
|
31
Option Care Health
OPCH
$4.7B
| $65.3M | 1% |
1,938,807
-345,486
| -15% | -$11.6M |
|
32
Insulet
PODD
$24.2B
| $62.9M | 0.96% |
289,900
+25,541
| +10% | +$5.54M |
|
33
Tandem Diabetes Care
TNDM
$834M
| $58.9M | 0.9% |
1,992,317
-150,452
| -7% | -$4.45M |
|
34
CRISPR Therapeutics
CRSP
$4.82B
| $56.4M | 0.86% |
900,400
+2,000
| +0.2% | +$125K |
|
|
ACCD
35
DELISTED
Accolade, Inc. Common Stock
ACCD
| $54.1M | 0.83% |
4,507,404
-20,519
| -0.5% | -$246K |
|
36
Idexx Laboratories
IDXX
$50.7B
| $52.2M | 0.8% |
94,110
-20,331
| -18% | -$11.3M |
|
37
ESSA Pharma
EPIX
$11.2M
| $52.1M | 0.8% |
7,898,583
| – | – |
|
38
Charles River Laboratories
CRL
$7.99B
| $51.5M | 0.79% |
217,756
-11,586
| -5% | -$2.74M |
|
39
Penumbra
PEN
$10.5B
| $51.1M | 0.78% |
203,046
-34,206
| -14% | -$8.6M |
|
40
Elevance Health
ELV
$72.4B
| $50.8M | 0.78% |
107,788
-66,099
| -38% | -$31.2M |
|
41
Exelixis
EXEL
$9.95B
| $50.6M | 0.77% |
2,108,100
-267,825
| -11% | -$6.43M |
|
42
Axsome Therapeutics
AXSM
$6.09B
| $50.6M | 0.77% |
635,372
+3,885
| +0.6% | +$309K |
|
43
Apellis Pharmaceuticals
APLS
$3.51B
| $49.2M | 0.75% |
821,800
+27,959
| +4% | +$1.67M |
|
44
CareDx
CDNA
$678M
| $47.5M | 0.73% |
3,954,792
+13,994
| +0.4% | +$168K |
|
|
45
Biohaven
BHVN
$1.71B
| $46M | 0.7% |
+1,075,000
| New | +$46M |
|
46
Humana
HUM
$37.5B
| $46M | 0.7% |
100,472
-69,574
| -41% | -$31.9M |
|
47
Bio-Rad Laboratories Class A
BIO
$7.8B
| $45.6M | 0.7% |
141,147
+6,817
| +5% | +$2.2M |
|
48
Inspire Medical Systems
INSP
$2.53B
| $43.9M | 0.67% |
215,600
+145,232
| +206% | +$29.5M |
|
49
Align Technology
ALGN
$9.59B
| $43.7M | 0.67% |
159,407
-7,479
| -4% | -$2.05M |
|
|
50
GE HealthCare
GEHC
$33B
| $41.4M | 0.63% |
535,184
+522,684
| +4,181% | +$40.4M |
|